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a  b  s  t  r  a  c  t
Prior  to the introduction  of  rotavirus  vaccines  in  2006,  rotavirus  was  the  leading  cause  of severe  gastroen-
teritis  among  European  children  <5 years  of  age.  We  conducted  a systematic  review  of the  published
literature  to examine  the effectiveness  and  impact  of  rotavirus  vaccines  in  Europe  following  the  ﬁrst
eight  years  of  routine  use.  Four  publication  databases  were  searched,  yielding  276  unique  citations  from
February  1st,  2006  to  July  31st,  2014.  Twenty  four  studies  on  effectiveness  (n =  9)  and impact  (n =  15)  met
the  inclusion  criteria.  Across  Europe,  vaccine  effectiveness  against  rotavirus-related  healthcare  utilisation
ranged  from  68%  to 98%, consistent  with  efﬁcacy  data  from  clinical  trials.  Reductions  in rotavirus  hospi-
talisations  ranged  from  65%  to 84%,  consistent  with  ﬁndings  from  post-marketing  studies  from  the US
and  Latin  America.  We  conﬁrm  the  signiﬁcant  public  health  beneﬁt  of  rotavirus  vaccination  in  Europe  and
provide further  evidence  to support  implementation  of  universal  rotavirus  vaccination  in all  European
countries.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Rotavirus is the leading cause of severe gastroenteritis in chil-
dren under ﬁve years of age [1]. Prior to the introduction of
rotavirus vaccines in Europe in 2006, it was estimated that 3.6
million episodes of rotavirus disease occurred annually among the
23.6 million children younger than 5 years of age [2]. Every year,
rotavirus accounted for 231 deaths, over 87,000 hospitalisations
and almost 700,000 outpatient visits in Europe [2].
In 2006, two rotavirus vaccines, Rotarix (GlaxoSmithKline, Rix-
ensart, Belgium) and RotaTeq (Merck and Co, Sanoﬁ Pasteur MSD,
Lyon, France) were licensed for use in Europe. Both live attenuated
rotavirus vaccines given orally have shown high efﬁcacy and good
safety proﬁles in large clinical trials [3,4]. Rotarix (RV1), which is
administered as a two-dose schedule, is a monovalent human vac-
cine originating from a G1P [8] strain [3]. RotaTeq (RV5), which
is administered as a three-dose schedule, is a pentavalent vac-
cine containing ﬁve human-bovine reassortant strains (G1, G2, G3,
G4, and P1A [8]) [4]. In the US, RV1 is administered at 2 and 4
months of age, and RV5 is administered at 2, 4 and 6 months of age.
However, the rotavirus vaccination schedules differ slightly across
Europe to better align with the timing of administration of other
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routine immunisations. For examples, in the United Kingdom (UK)
and Belgium RV1 is administered at 2 and 3 months of age, and in
Finland RV5 is administered at 2, 3 and 5 months of age.
In April 2009 the World Health Organization Strategic Advisory
Group of Experts (SAGE) recommended that all national immun-
isation programmes include rotavirus vaccination for infants [5].
Globally a number of countries have adopted this recommenda-
tion, however, only a limited number of European countries have
done so [6]. By the beginning of 2014, rotavirus vaccination had
been implemented nationally in Austria, Belgium, Luxembourg,
Finland, Greece, Norway, and the UK; with vaccination coverage
rates ranging from over 90% in the ﬁrst four countries to 23.4% in
Greece and less than 10% in Norway and the UK [6]. Many Euro-
pean countries are at various stages of issuing national or regional
recommendations or integrating rotavirus vaccination into their
national immunisation programmes.
Here, we summarise published data from the past eight years on
the effectiveness and impact of RV1 and RV5 in European countries
to generate a transparent base of evidence for policymakers across
Europe.
2. Methods
2.1. Search strategy
We developed search terms to identify articles published
between 1st February 2006 and July 31st 2014 reporting (1)
http://dx.doi.org/10.1016/j.vaccine.2015.03.016
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Table 1
PubMed literature search terms.
Strategy: Citations are identiﬁed that contain text in the
Title/Abstract/Keywords ﬁelds using the following strategy/search term
group. Case Reports, Randomised Controlled Trials, Animal Studies, Reviews
and Systematic Reviews were excluded where search engines allowed.
(Search Group 1) AND (Search Group 2) AND (Search Group 3) AND (Search
Group 4)
Date range (1st February 2006–31st July 2014)
Search Group 1: Disease Terms
“rotavirus”[MeSH] OR “rotavirus”[All Fields]
Search Group 2: Vaccine Terms
“rotavirus vaccines”[MeSH] OR (“rotavirus”[All Fields] AND (“vaccine”[All
Fields] OR (“vaccines”[All Fields])) OR “Rotarix”[MeSH] OR
“RotaTeq”[MeSH] OR “RV1”[MeSH] OR “RV5”[MeSH]
Search Group 3: Outcome Terms
“impact”[MeSH] OR “effect”[MeSH] OR “effectiveness”[MeSH] OR
“trends”[MeSH] OR “diarrhoea”[All Fields] OR “gastroenteritis”[All Fields]
OR “rotavirus disease”[All Fields] OR “hospitalisation”[All Fields] OR
“hospital admission”[All Fields] OR “outpatient”[All Fields] OR “visit”[All
Fields] OR “attendance”[All Fields] OR “consultation”[All Fields] OR “general
practice”[All Fields] OR “primary care”[All Fields] OR “Accident and
Emergency”[All Fields] OR “emergency department”[All Fields] OR
“laboratory conﬁrmed”[All Fields] OR “positive test”[All Fields] OR
“microbiologically conﬁrmed”[All Fields] OR “laboratory conﬁrmed”[All
Fields]
Search Group 4: Setting Terms (Countries in the WHO  European Region)
“European Union”[MeSH] OR “European countries”[MeSH] OR “European
Union”[MeSH] OR “Europe”[MeSH] OR “Austria”[All Fields] OR
“Belgium”[All Fields] OR “Finland”[All Fields] OR “Luxemburg”[All Fields]
OR “United Kingdom”[All Fields] OR “England”[All Fields] OR “Wales”[All
Fields] OR “Scotland”[All Fields] OR “Northern Ireland”[All Fields] OR
“Germany”[All Fields] OR “Armenia”[All Fields] OR “Moldova”[All Fields] OR
“Georgia”[All Fields] OR “Israel”[All Fields] OR “Albania”[All Fields] OR
“Andorra”[All Fields] OR “Azerbaijan”[All Fields] OR “Belarus”[All Fields] OR
“Bosnia and Herzegovina”[All Fields] OR “Bulgaria”[All Fields] OR
“Croatia”[All Fields] OR “Cyprus”[All Fields] OR “Czech Republic”[All Fields]
OR  “Denmark”[All Fields] OR “Estonia”[All Fields] OR “France”[All Fields] OR
“Greece”[All Fields] OR “Hungary”[All Fields] OR “Iceland”[All Fields] OR
“Ireland”[All Fields] OR “Italy”[All Fields] OR “Kazakhstan”[All Fields] OR
“Kyrgyzstan”[All Fields] OR “Latvia”[All Fields] OR “Lithuania”[All Fields] OR
“Malta”[All Fields] OR “Monaco”[All Fields] OR “Montenegro”[All Fields] OR
“Netherlands”[All Fields] OR “Norway”[All Fields] OR “Poland”[All Fields] OR
“Portugal”[All Fields] OR “Romania”[All Fields] OR “Russian Federation”[All
Fields] OR “Russia”[All Fields] OR “San Marino”[All Fields] OR “Serbia“[All
Fields] OR “Slovakia”[All Fields] OR “Slovenia”[All Fields] OR “Spain”[All
Fields] OR “Sweden”[All Fields] OR “Switzerland”[All Fields] OR
“Tajikistan”[All Fields] OR “Macedonia”[All Fields] OR “Turkey”[All Fields]
OR “Turkmenistan”[All Fields] OR “Ukraine”[All Fields] OR “Uzbekistan”[All
Fields]
vaccine effectiveness (VE) of rotavirus vaccines in preventing
rotavirus disease and/or healthcare utilisation due to rotavirus,
and/or (2) impact of rotavirus vaccination on rotavirus disease
trends and/or healthcare utilisation due to rotavirus (Table 1).
Studies from any country in the WHO  European Region [7] and
published in any European language were identiﬁed (Table 1). Case
Reports, Randomised Controlled Trials, Animal Studies, Reviews
and Systematic Reviews were excluded. Databases searched
included PubMed, Embase and Cochrane. We  also searched Google
Scholar and the System for Information on Grey Literature in Europe
(SIGLE) for relevant citations.
2.2. Inclusion criteria
We  reviewed the title and abstract of each article identiﬁed
using the search strategy to determine whether the article was
potentially relevant. The review was conducted by three reviewers
independently and discrepancies resolved by consensus between
reviewers. Potentially relevant articles were referred for a full
abstraction. Cohort, observational studies (case-control and pre- vs.
post-vaccine introduction time periods) and surveillance database
analyses performed under conditions of post-licensure routine
rotavirus vaccine use were included, as well as before/after studies
if the impact data (percentage change in crude or adjusted rates)
were provided or could be calculated. Studies reporting results in
both vaccine-eligible (direct effects) and/or in non-vaccine-eligible
age groups (indirect effects) were included. Health economic stud-
ies were excluded, along with time-series observational studies
with only post-vaccine introduction data, and studies conducted
among vulnerable populations not representative of the general
population.
2.3. Abstraction process
We  used EndNote X5 (Thomson Reuters) to organise and track
the articles, adding databases sequentially beginning with PubMed,
and performing automated and manual de-duplication following
the addition of each subsequent database. We double-abstracted
information about the study location, design, population charac-
teristics and size, type of vaccine, and vaccine coverage directly
into a customised Microsoft Excel spreadsheet. For outcomes of
interest we  abstracted information on number of events in the con-
trol (or pre-introduction) and intervention (or post-introduction)
groups, and effect measures (e.g. risk ratios). All included studies
were independently abstracted by three reviewers and harmonised
by consensus.
2.4. Data analysis
We  did not perform a meta-analysis because of the substantial
heterogeneity across studies. For example, studies that examined
time-trends used variable pre and post-vaccine year(s), with coun-
try speciﬁc differences in vaccine introduced, introduction date
and vaccine coverage rates. Among case-control studies, case def-
initions of rotavirus disease were based upon laboratory testing,
however, control groups varied between children with rotavirus
negative gastroenteritis, those admitted to hospital or attending
outpatient clinics for any reason other than gastroenteritis, as well
as healthy children in the community. Thus, we summarised the
data in descriptive analysis. For the analysis, the studies were
grouped by design based on whether they were reporting on vac-
cine effectiveness or impact. The results reported within each study
were then summarised by outcome and country.
3. Results
The systematic literature review yielded 276 unique citations
from 1st February 2006 to July 31st 2014 (Fig. 1). Of these we
reviewed 31 articles. Among these, 24 studies on the effectiveness
(n = 9) and impact (n = 15) of rotavirus vaccines met  the inclusion
criteria (Fig. 1).
3.1. Vaccine effectiveness (VE)
Nine studies evaluating VE were identiﬁed: one from Austria
[8], one from Belgium [9], one from Finland [10], one from Germany
[11], two from Israel [12,13] and three from Spain [14–16] (Table 2).
Seven studies looked at the combined VE of RV1 and RV5, one study
looked speciﬁcally at RV1 [13] and one speciﬁcally at RV5 [10].
3.1.1. VE against RVGE hospitalisations
Eight studies examined VE against rotavirus gastroenteritis
(RVGE) hospitalisations. The overall VE for at least one dose of
rotavirus vaccine ranged from 89.4% (95% CI 51.9–97.6%) to 95.6%
(95% CI 85.6–98.6%) (Table 3). The overall VE for fully vacci-
nated children ranged from 80% (95% CI 77–83%) to 98.3% (95% CI
87.4–99.8) (Table 3). One study from Spain examined VE separately
for RV1 and RV5 and found no signiﬁcant difference in effectiveness
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Table 2
Summary of vaccine effectiveness studies, Europe.
Country Vaccine Setting Season Outcome Cases/vaccinated Controls/not vaccinated Ref.
Austria RV1 + RV5 Paediatric wards 2010–2011 Hospitalisation for
laboratory-conﬁrmed
RVGE
211 Vaccinated 343 Unknown vaccination
status
[8]
Belgium RV1 + RV5 Hospitals with paediatric
beds
02/2008–06/2010 Hospitalisation for RVGE 215 Cases (gastroenteritis
in children who were
eligible for vaccination
(≥1dose))
276 Controls (children
admitted to/attending an
outpatient clinic for any
reason other than
gastroenteritis (same
hospital, time period, date
of  birth)
[9]
Finland RV5 University hospitals 2009–2012 Hospitalisation for RVGE 7 Cases (diarrhoea testing
positive for rotavirus in
hospitalised children)
73 Controls (diarrhoea
testing negative for
rotavirus in hospitalised
children)
[10]
Germany
(Mecklenburg-
Western
Pomerania)
RV1 + RV5 Nationwide notiﬁcation
and hospitalisation
surveillance data (from
laboratories and local
health authorities)
02/2009–06/2011 Laboratory-conﬁrmed RV
infections requiring
medical attention or
hospitalisation
114 Fully vaccinated (52
RV1, 34 RV5, 28 unknown)
901 Not vaccinated [11]
Israel RV1 + RV5 Hospitals 2007–2009 Hospitalisation for RVGE 111 Cases (diarrhoea
testing positive for
rotavirus)
216 Controls (diarrhoea
testing negative for
rotavirus)
[12]
Israel RV1 Health maintenance
organisation database
(community-based
post-marketing study)
2008–2009 Medical attention for AGE
in children over 12 months
7586 AGE episodes
requiring medical
attention in vaccinated
children (<12 mo)
18591 AGE episodes
requiring medical
attention in unvaccinated
children (<12 mo)
[13]
Spain (Castellon) RV1 + RV5 Microbiology Laboratory of
the General Hospital
2009 Cases of RV diarrhoea 71 Cases (diarrhoea cases
tested positive for
rotavirus only)
261 controls (diarrhoea
cases tested positive for
any other microorganisms
not rotavirus)
[14]
Spain (Navarre) RV1 + RV5 Clinical records from
paediatric hospitals and
primary health care centres
01/2008–06/2011 Medical attention for RVGE 756 Cases (conﬁrmed
rotavirus)
6036 Controls [15]
Spain RV1 + RV5 Paediatric research
network of primary,
emergency and hospital
care
10/2008–06/2009 Medical attention and
hospitalisation for RVGE
163 Vaccinated 304 Unvaccinated [16]
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Fig. 1. Database search algorithm used for systematic literature review.
between the two  vaccines [16]. VE for RV1 ranged from 90% (95%
CI 81–95%) to 97.5% (95% CI 81.5–99.6%) while VE for RV5 ranged
from 92.9% (95% CI 70–98.3%) to 95% (95% CI 63.1–99.3%).
In Belgium, VE was found to be very similar in younger children
(3–11 months) compared to older children (over 12 months): 93%
(95%CI 80–97%) vs. 89% (95% CI 75–95% for at least one dose of vac-
cine [9] (Table 3). In Germany VE for fully vaccinated children was
also found to be similar in the two age groups: 85% (95% CI 82–88%)
in children aged 18–29 months versus 80% (95% CI 77–83%) in chil-
dren aged 6–17 months [11]. Although the study in Belgium showed
that VE was higher for severe RVGE (91%, 95% CI 80–96%) com-
pared to mild or moderate RVGE (66%, 95% CI 31–91%) (Table 3),
this difference was not signiﬁcant.
3.1.2. VE against RVGE outpatient visits
Four studies examined VE against RVGE outpatient visits
(Table 3). VE for at least one dose of vaccine ranged from 50.1%
(95% CI 47.5–52.6%) to 83.5% (95% CI 25.4–96.3) (Table 3). VE in
fully vaccinated children ranged from 68% (95% CI 61–71%) to 75%
(95% CI 62–83%) (Table 3). VE was lower against RVGE outpatient
visits than that observed against RVGE hospitalisation [11,14,15]
(Table 3).
In Germany, Adlhoch et al. found that younger children had
higher VE against RVGE outpatient visits than older children (74%,
65% CI 69–78% vs. 57%, 95% CI 45–65%)[11]. In Israel children of high
socioeconomic status had higher VE against RVGE outpatient visits
compared to those from lower socioeconomic backgrounds (55.8%,
95% CI 52–59.5% vs 33.6%, 95% CI 27.7–39.3%) [12]. However, no
information was  given regarding the statistical signiﬁcance of these
differences.
3.1.3. VE against laboratory-conﬁrmed rotavirus infections
Three studies reported VE against all laboratory-conﬁrmed
rotavirus infections (Table 3). VE ranged from 87.7% (95% CI
45.5–99.7%) to 91.5% (95% CI 83.7–95.6%) for at least one dose of
vaccine, and from 78% (95% CI 68–85%) to 92.8% (95% CI 84.7–96.6%)
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Table  3
Vaccine effectiveness against RVGE hospitalisations and outpatient visits, and laboratory-conﬁrmed rotavirus infections, Europe.
Country VE for at least 1 dose of vaccine: % (95% CI) VE for full course of vaccine (2 doses of RV1 or
3  doses of RV5): % (95%CI)
Ref.
RVGE hospitalisation
Austria 2010: 95 (93–97)
2011:96 (95–97)
[8]
Belgium Overall: 91 (82–95)
3–11 mo:  93 (80–97)
≥12 mo: 89 (75–95)
Overall (RV1): 90 (81–95)
3–11 mo (RV1): 91 (75–97)
≥12 mo (RV1): 90 (76–96)
Severe RVGE (RV1): 91 (80–96)
Mild/Moderate RVGE (RV1): 66 (31–91)
[9]
Finland Overall (RV5): 92.1 (50.0–98.7) [10]
Germany (Mecklenburg-Western Pomerania) Overall: 80 (77–83)
6–17 mo:  80 (77–83)
18–29 mo: 85 (82–88)
[11]
Israel Overall: 89.4 (51.9–97.6) Overall: 88.9 (6.8–98.6) [12]
Spain (Castellon) Overall: 93.5 (30.7–99.3) [14]
Spain (Navarre) Overall: 83 (65–93) [15]
Spain Overall: 95.6 (85.6–98.6)
Overall (RV1): 97.5 (81.5–99.6)
Overall (RV5):92.9 (70–98.3)
Overall: 98.3 (87.4–99.8)
Overall (RV1): 97.3 (80.6–99.6)
Overall (RV5): 95 (63.1–99.3)
[16]
RVGE outpatient visits
Germany (Mecklenburg-Western Pomerania) Overall: 68 (61–71) [11]
6–17 mo:  74 (69–78)
18–29 mo: 57 (45–65)
Israel Overall (RV1): 50.1 (47.5–52.6) [13]
Low SES (RV1): 33.6 (27.7–39.3)
High SES (RV1): 55.8 (52–59.5)
Spain (Castellon) Overall: 83.5 (25.4–96.3) [14]
Spain (Navarre) Overall: 75 (62–83) [15]
RVGE outpatient visits
Laboratory-conﬁrmed rotavirus infections
Spain (Castellon) Overall: 87.7 (45.5–99.7) [14]
Spain (Navarre) Overall: 78 (70–84)
Overall (RV1): 76 (63–85)
Overall (RV5): 80 (69–87)
<24 mo:  80 (70–86)
≥24 mo: 61 (0–84)
Overall: 78 (68–85)
Overall (RV1): 75 (60–85)
Overall (RV5): 81 (68–89)
[15]
Spain Overall: 91.5 (83.7–95.6) Overall: 92.8 (84.7–96.6) [16]
for a full course of vaccination (Table 3). The two studies that com-
pared number of doses of vaccine given found very similar VE in
children having received at least one dose of vaccine and children
having completed their vaccination course [15,16].
The study in Navarre, Spain compared VE for RV1 and RV5 and
found very similar results for both vaccines: 76% (95% CI 63–85%)
for RV1 and 80% (95% CI 69–87%) for RV5, for at least one dose of
vaccine and 75% (95% CI 60–85%) for RV1 and 81% (95% CI 68–89%)
for RV5 for full course vaccination [15]. It also found that children
aged less than 24 months had signiﬁcantly higher VE (p = 0.0495)
than older children aged over 24 months (80%, 95% CI 70–86% vs
61%, 95% CI 0–84%) (Table 3).
3.2. Vaccine impact
Fifteen studies that assessed the impact of rotavirus vacci-
nation were included (Table 4). From countries where universal
rotavirus vaccination has been implemented we  included four stud-
ies from Austria [8,17–19], four from Belgium [20–23] and three
from Finland [10,24,25]. Studies using local or regional data from
countries at various stages of integrating rotavirus vaccination into
their national immunisation programmes included one from France
[26], one from Germany [27] and two from Spain [28,29].
3.2.1. Impact on RVGE/AGE hospitalisations
The impact of vaccination on RVGE hospitalisations was the
most commonly reported outcome (Table 5). Austria introduced
universal mass rotavirus vaccination in August 2007 [17]. The pro-
gramme  incorporated RV5 in 2007 and 2009, and RV1 in 2008
and 2010–2012 [8]. Vaccine coverage ranged from 72% in 2008
to 84% in 2011 [8,18]. In Austria, reductions in RVGE hospitalisa-
tions in infants aged less than 1 year ranged from 70% in 2008 to
84% in 2010 compared with the pre-vaccine period (2001–2006)
[8,17,18] (Table 5). RVGE hospitalisation rates remained low in chil-
dren between 2 and 3.5 years of age in 2011, suggesting sustained
protection of up to 3 years post-vaccination [18]. Reductions in
RVGE hospitalisations were also observed in children too old to
be eligible for rotavirus vaccination [8,18] suggesting indirect pro-
tection of these individuals (Table 5). However, in 2011 a distinct
increase in RVGE hospitalisations was  observed in children over 5
years of age compared to the pre-vaccine era [8]. Explanations for
this increase included deferred exposure, and change of age distri-
bution due to accumulation of risk of infection over time among
non-immune children, and/or very high rotavirus activity in 2011
[8].
Similarly, Belgium introduced rotavirus vaccines into the infant
immunisation schedule from 2006 [20]. From 2006 to 2008, 95%
of children receiving a rotavirus vaccine were given RV1 and 5%
received RV5 [23]. Overall vaccine coverage was estimated to be at
least 90% [21] and signiﬁcant reductions in RVGE hospitalisations
have been observed. One study, performed across 12 hospitals,
reported 65% to 80% reductions in RVGE hospitalisations in the
ﬁrst two years post-vaccination in the vaccine-eligible age group.
Reductions of 20% to 64% were observed in age groups too old or
too young to be eligible for vaccination [22] (Table 5).
In Finland, the national rotavirus immunisation programme
with RV5 started in 2009 [24]. Vaccine coverage is estimated to be
95% to 97% [24]. A national hospital database study comparing RVGE
and acute gastroenteritis (AGE) hospitalisations prior (1995–2005)
and after (2010) the start of the programme demonstrated a 80%
2102
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Table 4
Summary of vaccine impact studies, Europe.
Country, year of vaccine
introduction
Vaccine Study population Vaccine coverage
(%)
Study period Data source for RVGE cases Outcomes evaluated Ref.
Before After
Austria, 2007 aRV1 + RV5 Children <15 years 72 2001–2006 2008 Prospective surveillance
study; sentinel system in
11 hospitals
RVGE hospitalisation rates [17]
Austria, 2007 aRV1 + RV5 Children <15 years 74 2001–2005 2008–2009 Prospective surveillance
study; sentinel system in
11 hospitals
RVGE hospitalisation rates [18]
Austria, 2007 aRV1 + RV5 Children <15 years 78–84 2001–2005 2008–2011 Prospective surveillance
study; sentinel system in
11 hospitals
RVGE hospitalisation rates [8]
Austria, 2007 aRV1 + RV5 Children 0–18 years 72–74 2002–2005 2008–2009 Retrospective evaluation
study; 1 large tertiary care
hospital
Number of RVGE
hospitalisations
Number of RVGE
nosocomial infections
[19]
Belgium, 2006 aRV1 + RV5 Children <5 years 88 1986–2006 2007–2009 Prospective surveillance
study; sentinel system in 1
hospital
RVGE hospitalisations as
percentage of AGE
hospitalisations
[20]
Belgium, 2006 aRV1 + RV5 All age groups 90 1999–2006 2007–2010 Prospective surveillance
study; sentinel system of
microbiology laboratories
Number of
laboratory-conﬁrmed
rotavirus infections
[21]
Belgium, 2006 aRV1 + RV5 Children ≤5 years 85–90 2004–2006 2007–2009 Retrospective database
study; 12 hospitals
Number of RVGE
hospitalisations Number of
RVGE nosocomial
infections
[22]
Belgium, 2006 aRV1 + RV5 All age groups 90 2005–2006 2008 Prospective surveillance
study; sentinel system of
microbiology laboratories
Number of
laboratory-conﬁrmed
rotavirus infections
[23]
Finland, 2009 RV5 Children <5 years 95–97 1999–2005 2010 Retrospective national
database study; national
Hospital Discharge Register
RVGE/AGE hospitalisation
rates RVGE/AGE outpatient
visit rates
[24]
Finland, 2009 RV5 Children <16 years 95–97 2006–2008 2009–2011 Prospective surveillance
study; sentinel system in 1
hospital
Number of RVGE/AGE
hospitalisations umber of
RVGE/AGE outpatient visits
[25]
Finland, 2009 RV5 Children <16 years 95–97 2001–2006 2009–2012 Retrospective database
study; 2 hospitals
RVGE/AGE hospitalisation
rates
[10]
France, 2007 RV5 Children <2 years 47 2002–2007 2008–2009 Population-based
prospective cohort study;
catchment area of 1
hospital
RVGE hospitalisation rates [26]
Germany, 2006 RV1 + RV5 All age groups 22 WFS
58 EFS
2004–2006 2008–2011 Retrospective national
database study; national
disease reporting system
RVGE hospitalisation rates [27]
Spain, 2007 RV1 + RV5 Children <5 years 38 2005–2006 2009 Retrospective national
database study; national
Hospital Discharge
database
RVGE/AGE hospitalisation
rates
[28]
Spain, 2007 RV1 + RV5 Children <5 years 46 2003–2007 2008–2010 Retrospective database
study; 32 hospitals
RVGE/AGE hospitalisation
rates
[29]
a National immunisation programme has incorporated RV1 (Rotarix) and RV5 (Rotateq).
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Table 5
Impact of vaccination on RVGE hospitalisations, nosocomial infections and outpatient visits, and laboratory-conﬁrmed rotavirus infections, Europe.
Country Vaccine Outcome measured Pre-vaccination Post-vaccination Vaccination impact %
Change (95% CI)
Ref.
Year Result Year Result
RVGE hospitalisation
Austria aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
children (extrapolated to whole country from
surveillance system)
2001–2006 <1 yr: 2066
1 yr: 1822
2–4 yrs: 436
5–14 yrs: 34
2008 <1 yr: 631
1 yr:1456
2–4 yrs: 461
5–14 yrs: 34
−70
−20
+6
0
[17]
Austria aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
children (extrapolated to whole country from
surveillance system)
2001–2005 <1 yr: 2141
1 yr: 1745
2–4 yrs: 394
5–14 yrs: 31
2009 <1 yr: 441
1 yr:408
2–4 yrs: 256
5–14 yrs: 19
−79
−76
−35
−38
[18]
Austria aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
children (extrapolated to whole country from
surveillance system)
2001–2005 <1 yr: 2141
1 yr: 1745
2–3.4 yrs: 611
3.5–4 yrs: 206
5–9 yrs: 53
10–14 yrs: 13
2010
2011
<1 yr: 344
1 yr: 331
2–3.4 yrs: 235
3.5–4 yrs: 188
5–9 yrs: 35
10–14 yrs: 6
<1 yr: 397
1 yr: 332
2–3.4 yrs: 216
3.5–4 yrs: 201
5–9 yrs: 78
10–14 yrs: 14
−84
−81
−62
−9
−34
−32
−81
−81
−65
−3
+48
+6
[8]
Austria aRV1 + RV5 Annual number of RVGE hospitalisations 2002–2005 <1 yr: 90
0–18 yrs: 257
2008–2009 <1 yr: 11
0–18 yrs: 67
−88
−74
[19]
Belgium aRV1 + RV5 Annual RVGE hospitalisations as a percentage
of annual total AGE hospitalisations
1986–2006 <5 yrs:19% 2007
2008
2009
<5 yrs: 12%
<5 yrs: 10%
<5 yrs: 6%
−35
−49
−66
[20]
Belgium aRV1 + RV5 Annual number of RVGE hospitalisations 2004–2006 <2 mo:  44
2–24 mo:  716
>24 mo:  121
2008
2009
<2 mo:  22
2–24 mo: 249
>24 mo:  97
<2 mo:  16
2–24 mo: 140
>24 mo:  43
−50 (−64 to −36)
−65 (−69 to −62)
−20 (−28 to −14)
−64 (−76 to −49)
−80 (−83 to −77)
−64 (−72 to −56)
[22]
Finland RV5 Annual RVGE hospitalisation rates/1000
person years
Annual AGE hospitalisation rates/1000 person
years
1999–2005
1999–2005
<1 yr: 4.9
1 yr: 5.7
2 yrs: 2.7
3 yrs: 1.3
4 yrs: 0.7
<1 yr: 20
1 yr: 21
2 yrs: 10
3 yrs: 6
4 yrs: 4
2010
2010
<1 yr: 1.0
1 yr: 1.5
2 yrs: 0.8
3 yrs: 0.4
4 yrs: 0.3
<1 yr: 9
1 yr: 9
2 yrs: 5
3 yrs: 3
4 yrs: 3
−80 (−85 to −75)
−74 (−79 to −68)
−70 (−77 to −60)
−69 (−80 to −54)
−53 (−70 to −26)
−54 (−58 to −50)
−55 (−59 to −51)
−51 (−56 to −45)
−47 (−54 to −39)
−27 (−37 to −15)
[24]
Finland RV5 Annual number of RVGE hospitalisations
Annual number of AGE hospitalisations
2006–2008
2006–2008
<16 yrs: 219
<16 yrs: 434
2009–2011
2009–2011
<16 yrs: 52
<16 yrs: 186
−76
−57
[25]
Finland RV5 Annual RVGE hospitalisation rates/1000
children
Annual AGE hospitalisation rates/1000
children
2001–2006
2001–2006
<16 yrs: 0.66
<16 yrs: NR b
2009–2012
2009–2012
<16 yrs: 0.14
<16 yrs: NR
−78
−57
[10]
France RV5 Annual number of RVGE hospitalisations 2002–2007 <2 yrs: 61 2008–2009 <2 yrs: 30 −51 [26]
Germany aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
population
2004–2006 WFS
<2 yrs: NR
EFS
<2 yrs: NR
2008–2011 WFS
<2 yrs: NR
EFS
<2 yrs: NR
−25
−36
[27]
2104
 
E.
 K
araﬁllakis
 et
 al.
 /
 V
accine
 33
 (2015)
 2097–2107
Table 5 (Continued)
Country Vaccine Outcome measured Pre-vaccination Post-vaccination Vaccination impact %
Change (95% CI)
Ref.
Year Result Year Result
Spain aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
children
Annual AGE hospitalisation rates/100,000
children
2005–2006
2005–2006
<1 yr: 835
<5 yrs: 278
<1 yr: 2741
<5 yrs: 1156
2009
2009
<1 yr: 477
<5 yrs: 174
<1 yr: 1584
<5 yrs: 749
−43
−37
−42
−35
[28]
Spain aRV1 + RV5 Annual RVGE hospitalisation rates/100,000
children
Annual AGE hospitalisation rates//100,000
children
2003–2007
2003–2007
<5 yrs: 298
<5 yrs: 600
2008–2009
2009–2010
2008–2009
2009–2010
<5 yrs: 254
<5 yrs: 165
<5 yrs: 420
<5 yrs: 306
−15
−45
−30
−49
[29]
Nosocomial RVGE
Austria aRV1 + RV5 Annual number of RVGE nosocomial infections 2002–2005 <1 yr: 14
0–18 yrs: 27
2008–2009 <1 yr: 1
0–18 yrs: 2
−97
−93
[19]
Belgium aRV1 + RV5 Annual number of RVGE nosocomial infections 2004–2006 ≤5 yrs: 140 2008
2009
≤5 yrs: 75
≤5 yrs: 33
−46
−76
[22]
Germany aRV1 + RV5 Annual RVGE nosocomial infection
rates/100,000 population
2004–2006 WFS
<6 mo: 156
6–11 mo:  108
12–17 mo:  59
18–23 mo:  35
2–4 yrs: 10
EFS
<6 mo: 214
6–11 mo:  148
12–17 mo:  109
18–23 mo:  54
2–4 yrs: 29
2008–2011 WFS
<6 mo:  117
6–11 mo: 66
12–17 mo:  57
18–23 mo:  36
2–4 yrs: 9
EFS
<6 mo:  225
6–11 mo: 94
12–17 mo:  79
18–23 mo:  36
2–4 yrs: 23
−25
−38
−4
+1
−5
+5
−36
−28
−33
−20
[27]
RVGE outpatient visits
Finland RV5 Annual RVGE outpatient visit rates/1000
person years
Annual AGE outpatient visit rates/1000 person
years
1999–2005
1999–2005
<1 yr: 0.4
1 yr: 0.4
2 yrs: 0.3
3 yrs: 0.09
4 yrs: 0.08
<1 yr: 22
1 yr: 19
2 yrs: 10
3 yrs: 6
4 yrs: 4
2010
2010
<1 yr: 0.08
1 yr: 0.1
2  yrs: 0.15
3 yrs:0.07
4 yrs: 0.02
<1 yr: 19
1 yr: 17
2  yrs: 8
3 yrs: 6
4 yrs: 5
−79 (−91 to −48)
−73 (−88 to −39)
−43 (−71 to 13)
−30 (−75 to 97)
−79 (−97 to 55)
−13 (−18 to −7)
−11 (−16 to −5)
−22 (−29 to −14)
−1 (−11 to 10)
+27 (−12 to 43)
[24]
Finland RV5 Annual number of RVGE outpatient visits
Annual number of AGE outpatient visits
2006–2008
2006–2008
<16 yrs: 177
<16 yrs: 375
2009–2011
2009–2011
<16 yrs: 34
<16 yrs: 144
−81
−62
[25]
Laboratory-conﬁrmed rotavirus infections
Belgium aRV1 + RV5 Annual number of laboratory-conﬁrmed
rotavirus infections
1999–2006 NR (monthly counts
shown on graph)
2007–2010 NR (monthly counts
shown on graph)
−50 [21]
Belgium aRV1 + RV5 Annual number of laboratory-conﬁrmed
rotavirus infections
2005–2006 6383 2008 2464 −61% (−63 to −60) [23]
a National immunisation programme has incorporated RV1 (Rotarix) and RV5 (Rotateq).
b NR: data not reported.
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reduction in RVGE hospitalisations among infants aged less than 1
year of age and 54% when the total inpatient AGE burden was con-
sidered in the same age group [24] (Table 5). Reductions of 53% to
74% and 27% to 55% in RVGE and AGE hospitalisations, respectively,
were observed in age groups too old to be eligible for rotavirus
vaccination [24] (Table 5). Further studies conducted in individ-
ual hospitals reported similar reductions in childhood RVGE and
AGE hospitalisations compared with the pre-vaccine period [10,25]
(Table 5).
In the absence of a national rotavirus vaccination programme
in France a study performed in the city of Brest found that RVGE
hospitalisations in children less than 2 years of age declined by
51% compared with the pre-vaccination period. This was consistent
with the estimated vaccine coverage of 47% with RV5, which was
the only vaccine used in the region [26] (Table 5). No reduction was
observed in age groups over 2 years of age [26].
In Germany, rotavirus vaccines have been available on the mar-
ket since 2006. However, rotavirus vaccination (RV1 and RV5) has
been included in the routine vaccination scheme in only ﬁve of the
16 federal states since 2008 [27]. In 2010 a moderate (58%) and low
(22%) vaccine uptake was observed in the ﬁve eastern federal states
(EFS) and the 11 western federal states (WFS), respectively [27]. A
study using the national mandatory disease reporting system found
that RVGE hospitalisations in children less than 2 years of age were
reduced by 36% and 25% in EFS and WFS, respectively, in post-
vaccine seasons (2008–2011) compared to pre-vaccine seasons
(2004–2006) [27] (Table 5). No signiﬁcant reduction was observed
in age groups over 2 years of age [27].
In Spain, rotavirus vaccines have been available since 2006 (RV1)
and 2007 (RV5) but they are neither funded nor reimbursed by the
National Health System [29]. Overall vaccine coverage in 2009 was
38% [28]. A national hospital database study comparing RVGE and
AGE hospitalisations prior (2005–2006) and after (2009) vaccine
introduction demonstrated a 43% reduction in RVGE hospitalisa-
tions among infants less than 1 year of age and a 42% reduction
in total AGE hospitalisations in the same age group [28] (Table 5).
Hospitalisation rates for RVGE and AGE in children less than 5 years
of age were 37% and 35% lower [28] (Table 5). A regional study per-
formed in Galicia (North-western Spain), where vaccine coverage
was estimated to be 49%, reported similar reductions in childhood
RVGE and AGE hospitalisations compared with the pre-vaccine
period. Hospitalisation rates for RVGE and AGE in children less than
5 years of age were 45% and 49% lower, respectively [29] (Table 5).
In 2010, the Spanish Drugs and Health Products Agency did not
authorise the release of new batches of the two vaccines onto the
Spanish market for ﬁve months (June to November 2010) due to
the detection of circovirus in both vaccines [30]. The withdrawal of
RV1 in Spain still remains, so currently only RV5 is available. The
impact of this temporary withdrawal was evaluated in Galicia [31]
as an extension of the previous study [29]. A sudden drop in vac-
cine coverage was observed from 49% to 22% [31]. A rebound 260%
increase in RVGE hospitalisations in children less than 12 months
of age was observed in 2010–2011 compared to the previous sea-
son [31]. In 2011–2012, once rotavirus vaccination was  resumed,
rates decreased by 30% compared to 2010–2011 [31].
3.2.2. Impact on nosocomial RVGE infections
In Austria, a 93% reduction in hospital-acquired rotavirus infec-
tions in 0–18 year olds was reported from one large tertiary
hospital during 2008–2009 compared to the pre-vaccine period
(2002–2005) (Table 5) [19]. The largest decrease in nosocomial
cases was in infants aged less than 1 year (97%) [19]. Similarly
in Belgium, hospital-acquired rotavirus infections in children less
than 5 years of age declined by 46% to 76% post-vaccination
[22] (Table 5). In Germany, the largest reductions in nosocomial
rotavirus infections were in infants 6–11 months of age (36% and
38% in EFS and WFS, respectively) [27] (Table 5).
3.2.3. Impact on RVGE/AGE outpatient visits
In Finland a national hospital database study comparing RVGE
and AGE outpatient visits prior (1995–2005) and after (2010) the
start of vaccination demonstrated a 79% reduction in RVGE outpa-
tient visits among infants less than 1 year of age and 13% when the
total AGE outpatient visits burden was considered in the same age
group [24] (Table 5). Reductions of 30% to 79% in RVGE outpatient
visits were observed in age groups too old to be eligible for rotavirus
vaccination [24] (Table 5). A further study conducted in a single hos-
pital in Finland reported similar reductions in childhood RVGE and
AGE outpatient visits compared with the pre-vaccine period [25]
(Table 5).
3.2.4. Impact on laboratory-conﬁrmed rotavirus infections
In Belgium, vaccine impact measured through national sentinel-
based surveillance systems have reported a 50% to 61% decline in
the number of laboratory-conﬁrmed rotavirus infections in all age
groups in post-vaccination years compared to the pre-vaccine era
[21,23] (Table 5). The greatest reductions were observed in infants
aged less than 1 year (80%) [23].
4. Discussion
Eight years after their initial introduction in Europe, rotavirus
vaccines have shown to be highly effective with substantial impact
against RVGE-related healthcare utilisation, including hospitalisa-
tions, nosocomial infections and outpatient visits. These ﬁndings
are consistent across studies and countries in Europe and compa-
rable to observations from Australia [32] and the US [33].
Overall, the estimates of vaccine effectiveness from studies of
rotavirus vaccines in routine use in Europe were consistent with
data from clinical trials [3,34]. Estimates of effectiveness for a com-
plete course of RV1 or RV5 in case-control studies in Europe against
RVGE hospitalisation or RVGE outpatient visits ranged from 68%
to 98% depending on the study and selected control group [8–16].
These compare with vaccine efﬁcacy of 90% and 98% against severe
RVGE, and 79% and 68% against RVGE of any severity reported in
European clinical trials for RV1 and RV5, respectively [3,34]. Addi-
tional years of experience will provide more complete estimates of
effectiveness, and enable documentation of any potential waning
immunity. Future VE studies in Europe will need to demonstrate
whether or not effectiveness is sustained in older children, and
whether these vaccines provide protection against a range of hete-
rotypic circulating rotavirus strains in Europe. This will provide
further evidence that rotavirus vaccines perform well even against
non-vaccine genotypes, which would be consistent with ﬁndings
from clinical efﬁcacy trials [3,34] as well as from post-licensure
studies from the US [33] and Latin America [35].
The impact of RV1 and RV5 in Europe is evident not only in
the changing epidemiology of rotavirus activity, but also in the
reduction of healthcare utilisation due to diarrhoeal disease. From
countries in Europe where universal rotavirus vaccination has
been implemented, studies summarised in this review have esti-
mated 65% to 84% reductions in rotavirus hospitalisations in vaccine
eligible children following vaccine introduction [8,10,17–25]. Addi-
tionally, despite the fact that the greatest impact was observed
in infants, signiﬁcant reductions were also seen in older children
and adults, suggesting herd immunity. The reduction in RVGE/AGE
hospitalisations and outpatient visits could represent large health-
care cost savings attributable to rotavirus vaccination and should
be accounted for in subsequent European cost-effectiveness stud-
ies for rotavirus vaccines, which have so far only considered cost
beneﬁts afforded by direct protection of infants [36–38].
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Reductions have also been observed among unvaccinated indi-
viduals, providing evidence of indirect impact of rotavirus vaccines.
Although these reductions could be attributed to the natural
seasonal ﬂuctuations in rotavirus activity, they are signiﬁcantly
more pronounced than the historical long-term patterns typically
observed for rotavirus. Recent research in Austria and Finland sug-
gests these reductions have been sustained for up to four seasons
[8,10]. It will be important, however, to continue monitoring these
trends over time to conﬁrm the long-term impact of rotavirus
vaccination in Europe. In addition, continued monitoring will
allow characterisation of the evolving epidemiology of rotavirus
genotypes. Reductions in rotavirus hospitalisations in Europe are
consistent with the estimated 50% to 90% reduction reported in
the US [33]. These substantial beneﬁts have been observed with
only rare adverse events, such as intussusception, reported in post-
marketing studies in the US, Australia and Latin America [39]. In
these countries the morbidity and mortality averted by vaccina-
tion has been shown to outweigh even the most liberal estimates
of increased risk [39]. Further quantiﬁcation of this risk in Europe
is necessary.
Having said, that it’s important to note that studies looking at
vaccine impact have similar limitations. Their designs are descrip-
tive and ecological and, therefore, the effects measured may  be due
to other factors not related to immunisation. First, rotavirus testing
practices could have changed in the post-vaccination period. Sec-
ond, the accuracy of hospital diagnoses codes depends on clinical
diagnoses recorded in patients’ medical records. Coding practices
could have changed over time. Last, there is natural year-to-year
variability in the size of the rotavirus season. It remains a possibil-
ity that at least some of the observed decrease may  be due to a less
active rotavirus year, independent of vaccination effect.
In summary, this systematic review conﬁrmed the signiﬁcant
public health beneﬁt of rotavirus vaccination in Europe as an
important tool for protecting children against severe acute gas-
troenteritis. Since its introduction in 2006, it has contributed to a
signiﬁcant reduction in burden of RVGE through direct and indirect
effects. Furthermore, the vaccine effectiveness observed under rou-
tine use is consistent with efﬁcacy data from clinical trials. These
beneﬁts were observed consistently across all European countries
in which it has been introduced as part of the routine childhood
immunisation schedule. Thus, we provide further evidence to sup-
port the implementation of universal rotavirus vaccination in all
European countries.
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